Media headlines about Corvus Pharmaceuticals (NASDAQ:CRVS) have been trending somewhat positive on Wednesday, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Corvus Pharmaceuticals earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned news articles about the company an impact score of 45.7702170733168 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Shares of Corvus Pharmaceuticals traded down $0.41, hitting $11.55, during midday trading on Wednesday, according to Marketbeat. The stock had a trading volume of 1,175 shares, compared to its average volume of 148,037. The stock has a market capitalization of $357.91 million, a P/E ratio of -4.28 and a beta of -2.13. Corvus Pharmaceuticals has a fifty-two week low of $7.42 and a fifty-two week high of $17.64.
Corvus Pharmaceuticals (NASDAQ:CRVS) last released its earnings results on Thursday, May 3rd. The company reported ($0.63) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.74) by $0.11. equities research analysts forecast that Corvus Pharmaceuticals will post -2.81 earnings per share for the current year.
Several equities analysts have issued reports on the company. ValuEngine downgraded Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, May 14th. BidaskClub raised Corvus Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, May 25th. Zacks Investment Research raised Corvus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $11.00 target price for the company in a research note on Thursday, May 10th. Finally, Jefferies Financial Group began coverage on Corvus Pharmaceuticals in a research note on Tuesday, June 5th. They issued a “buy” rating and a $17.00 target price for the company. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Corvus Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $17.75.
Corvus Pharmaceuticals Company Profile
Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint.
Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.